ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

Oral Session Title: ART Offspring           

Monday, October 14, 2019        10:45 am-12:15 pm Eastern Daylight Time (EDT)

Abstract O-16 – 11:30 AM EDT: “Babies Born Following Administration of Nolasiban Before Embryo Transfer (ET) After IVF: Neonatal And Infant Development Outcomes From a Double-Blind, Placebo-Controlled, Clinical Trial.”

Poster Presentation Session Topic: Endometriosis

Wednesday, October 16, 2019  6.30am-7.45am Eastern Daylight Time (EDT)

Abstract P-539: “Long Term Treatment of Endometriosis Associated Pain (EAP) with Linzagolix: Efficacy and Safety after 12 Months of Treatment.”

ObsEva will also be at Booth # 1005 of the exhibition hall.

Leave a Reply

Your email address will not be published. Required fields are marked *